COMPARATIVE COST EFFECTIVENESS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION

被引：0
|
作者：
Gravlee, E. [1 ]
Prajapati, P. [1 ]
机构：
[1] Univ Mississippi, Oxford, MS USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE381
引用
收藏
页码：S409 / S410
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [2] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. CIRCULATION, 2022, 146
  • [3] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    [J]. CIRCULATION, 2020, 142
  • [4] Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States
    Nechi, Regina Nwamaka
    Rane, Amey
    Karaye, Rukayyah M.
    Ndikumukiza, Cyrille
    Alsahali, Saud
    Jatau, Abubakar I.
    Zoni, Cesar Rodrigo
    Alanzi, Abdullah
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    [J]. CLINICAL THERAPEUTICS, 2023, 45 (07) : 627 - 632
  • [5] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    [J]. JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [6] Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis
    Rane, Amey
    Nechi, Regina Nwamaka
    Imam, Maryam
    Zoni, Cesar Rodrigo
    Ndikumukiza, Cyrille
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    Alanzi, Abdullah
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (09): : 1045 - 1053
  • [7] Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
    Sang, Haiqiang
    Wan, Yiming
    Ma, Zhenzhou
    Zhang, Shengye
    Zhao, Qiuping
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [8] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [9] EVALUATION OF THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN FOR TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE UNITED STATES
    Nechi, R.
    Rane, A.
    Karaye, R.
    Ndikumukiza, C.
    Alsahali, S.
    Jatau, A.
    Zoni, C. R.
    Alanazi, A.
    Karaye, I
    Yunusa, I
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S122 - S122
  • [10] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
    Rane, A.
    Nechi, R. N.
    Imam, M.
    Zoni, C. R.
    Ndikumukiza, C.
    Karaye, I
    Yunusa, I
    Alanazi, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S99 - S99
12345